Home › Companies › ZENTALIS PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and ZENTALIS PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-21 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Proxy season: 2023-2024 2024-2025
Explore ZENTALIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are ZENTALIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Kimberly Blackwell, M.D. | 48,055,584 | -- | -- | 12,810,370 | 5,241,491 | Majority: yes |
| Elect Director: Enoch Kariuki, Pharm.D. | 45,008,378 | -- | -- | 15,857,576 | 5,241,491 | Majority: yes |
| Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 66,098,083 | 5,665 | 3,697 | -- | 0 | Majority: yes |
| Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. | 36,128,130 | 24,729,730 | 8,094 | -- | 5,241,491 | Passed |
Source: ZENTALIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-21 — read the filing on EDGAR.
Each item below shows how the 148 asset managers that disclosed a ZENTALIS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
59% Passed · of votes cast
ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”): 36,128,130 for, 24,729,730 against — passed, per its Form 8-K filed 2024-06-21 (Item 5.07). Of all 71,013,233 outstanding shares: 50.9% for, 35% against (86% of the company cast a for/against vote).
The 147 asset managers below cast 49.8% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,401 | 14,238,710 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 11,557,422 | 0 | 0 | 0 | For |
| Matrix Capital Management Company, LP | 11,545,757 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 10,347,704 | 0 | 0 | Against |
| Capital Group | 0 | 5,639,328 | 0 | 0 | Against |
| Vanguard | 4,318,674 | 0 | 0 | 0 | For |
| Federated Hermes | 3,463,600 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 3,070,442 | 0 | 0 | 0 | For |
| BlackRock | 2,151,772 | 8,201 | 0 | 0 | For |
| MPM BioImpact LLC | 1,526,593 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 0 | 1,141,610 | 0 | 0 | Against |
| State Street | 510 | 1,095,216 | 0 | 0 | Against |
| Verition Fund Management LLC | 0 | 1,079,807 | 0 | 0 | Against |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 0 | 961,486 | 0 | 0 | Against |
| Charles Schwab | 0 | 914,392 | 0 | 0 | Against |
| PRIMECAP Odyssey Funds | 0 | 850,250 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 708,586 | 0 | 0 | Against |
| Paradigm Biocapital Advisors LP | 0 | 669,336 | 0 | 0 | Against |
| Citadel | 513,797 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 488,590 | 0 | 0 | 0 | For |
| Boxer Capital, LLC | 450,000 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 304,344 | 0 | 0 | Against |
| Equitable | 90,140 | 75,423 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 158,906 | 0 | 0 | Against |
| Rafferty Asset Management, LLC | 0 | 158,906 | 0 | 0 | Against |
Showing the 25 largest of 147 asset managers. See all 147 in the interactive database.
Combines 4 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Enoch Kariuki, Pharm.D.”): 45,008,378 for, 15,857,576 withheld, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,013,233 outstanding shares: 63% for, 22% withheld (86% of the company cast a for/withheld vote).
The 58 asset managers below cast 99.9% of the shares they voted on this item FOR (26,053,408 for, 3,793 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 11,557,422 | 0 | 0 | 0 | For |
| Fidelity | 641,076 | 0 | 5,807,130 | 0 | Abstain |
| Vanguard | 4,242,938 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,724,769 | 0 | 1,423,364 | 0 | For |
| Capital Group | 2,819,664 | 0 | 0 | 0 | For |
| Federated Hermes | 1,731,800 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 850,250 | 0 | 0 | 0 | For |
| BlackRock | 661,019 | 0 | 0 | 0 | For |
| Charles Schwab | 457,196 | 0 | 0 | 0 | For |
| State Street | 255 | 0 | 244,906 | 0 | Abstain |
| Equitable | 109,045 | 0 | 56,518 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 158,906 | 0 | Abstain |
| John Hancock | 52,198 | 0 | 31,485 | 0 | For |
| TIAA | 0 | 0 | 80,808 | 0 | Abstain |
| ProShares | 0 | 0 | 59,364 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 55,570 | 0 | Abstain |
| Northwestern Mutual | 0 | 0 | 42,509 | 0 | Abstain |
| Brighthouse | 24,859 | 0 | 13,927 | 0 | For |
| SEI | 32,540 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 29,453 | 0 | 0 | 0 | For |
| Thrivent | 0 | 0 | 27,707 | 0 | Abstain |
| Global X | 26,545 | 0 | 0 | 0 | For |
| Voya | 19,243 | 0 | 0 | 0 | For |
| Pacific Life | 18,887 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 18,478 | 0 | Abstain |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kimberly Blackwell, M.D.”): 48,055,584 for, 12,810,370 withheld, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,013,233 outstanding shares: 68% for, 18% withheld (86% of the company cast a for/withheld vote).
The 58 asset managers below cast 99.9% of the shares they voted on this item FOR (27,984,776 for, 3,793 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 11,557,422 | 0 | 0 | 0 | For |
| Fidelity | 641,076 | 0 | 5,807,130 | 0 | Abstain |
| Vanguard | 4,242,938 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,148,133 | 0 | 0 | 0 | For |
| Capital Group | 2,819,664 | 0 | 0 | 0 | For |
| Federated Hermes | 1,731,800 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 850,250 | 0 | 0 | 0 | For |
| BlackRock | 661,019 | 0 | 0 | 0 | For |
| Charles Schwab | 457,196 | 0 | 0 | 0 | For |
| State Street | 244,831 | 0 | 330 | 0 | For |
| Equitable | 165,563 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 158,906 | 0 | Abstain |
| John Hancock | 61,781 | 0 | 21,902 | 0 | For |
| TIAA | 80,808 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 59,364 | 0 | Abstain |
| Lincoln Financial | 49,500 | 0 | 6,070 | 0 | For |
| Northwestern Mutual | 42,509 | 0 | 0 | 0 | For |
| Brighthouse | 24,859 | 0 | 13,927 | 0 | For |
| SEI | 32,540 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 29,453 | 0 | 0 | 0 | For |
| Thrivent | 0 | 0 | 27,707 | 0 | Abstain |
| Global X | 26,545 | 0 | 0 | 0 | For |
| Voya | 19,243 | 0 | 0 | 0 | For |
| Pacific Life | 18,887 | 0 | 0 | 0 | For |
| JPMorgan | 18,478 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 66,098,083 for, 5,665 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,013,233 outstanding shares: 93% for, 0.1% against (93% of the company cast a for/against vote).
The 58 asset managers below cast 100% of the shares they voted on this item FOR (34,184,106 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 11,557,422 | 0 | 0 | 0 | For |
| Fidelity | 6,448,206 | 0 | 0 | 0 | For |
| Vanguard | 4,242,938 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,148,133 | 0 | 0 | 0 | For |
| Capital Group | 2,819,664 | 0 | 0 | 0 | For |
| Federated Hermes | 1,731,800 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 850,250 | 0 | 0 | 0 | For |
| BlackRock | 661,019 | 0 | 0 | 0 | For |
| Charles Schwab | 457,196 | 0 | 0 | 0 | For |
| State Street | 245,161 | 0 | 0 | 0 | For |
| Equitable | 165,563 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 158,906 | 0 | 0 | 0 | For |
| John Hancock | 83,683 | 0 | 0 | 0 | For |
| TIAA | 80,808 | 0 | 0 | 0 | For |
| ProShares | 59,364 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,570 | 0 | 0 | 0 | For |
| Northwestern Mutual | 42,509 | 0 | 0 | 0 | For |
| Brighthouse | 37,488 | 0 | 1,298 | 0 | For |
| SEI | 32,540 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 29,453 | 0 | 0 | 0 | For |
| Thrivent | 27,707 | 0 | 0 | 0 | For |
| Global X | 26,545 | 0 | 0 | 0 | For |
| Voya | 19,243 | 0 | 0 | 0 | For |
| Pacific Life | 18,887 | 0 | 0 | 0 | For |
| JPMorgan | 18,478 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
Ranked by the number of ZENTALIS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 71,013,233 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 20.09% |
| 2 | MUTUAL FUND SERIES TRUST | 16.28% |
| 3 | Matrix Capital Management Company, LP | 16.26% |
| 4 | T. Rowe Price | 14.57% |
| 5 | Capital Group | 7.94% |
| 6 | Vanguard | 6.08% |
| 7 | Federated Hermes | 4.88% |
| 8 | Decheng Capital LLC | 4.32% |
| 9 | BlackRock | 3.04% |
| 10 | MPM BioImpact LLC | 2.15% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Matrix Capital Management Master Fund, LP | 19.66% | DEF14A |
| Eventide Asset Management, LLC | 16.28% | DEF14A |
| FMR LLC | 14.56% | DEF14A |
| Citadel Advisors | 5.46% | 13F |
| State Street | 5.33% | 13F |
| T. Rowe Price | 4.91% | 13F |
| Vanguard Group | 4.09% | 13F |
| Morgan Stanley | 1.98% | 13F |
| Kimberly Blackwell, M.D. | 1.91% | DEF14A |
| BlackRock | 1.76% | 13F |
Percentages above are of 71,013,233 shares outstanding, as reported by ZENTALIS PHARMACEUTICALS INC. on its Form 10-Q dated 2024-05-03 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ZENTALIS PHARMACEUTICALS INC.’s 10-Q dated 2024-05-03. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At ZENTALIS PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-21, in the 2023-2024 proxy season, 148 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,007 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of our named executive… — the proposal passed with 59% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ZENTALIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-21.
ZENTALIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.